Raymond P Perez

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. ncbi New targets and challenges in the molecular therapeutics of cancer
    Alan Eastman
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Br J Clin Pharmacol 62:5-14. 2006
  2. ncbi Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 13:3293-301. 2007
  3. ncbi Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
    Raymond P Perez
    Section of Hematology Oncology, Department of Medicine, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 12:7079-85. 2006
  4. ncbi Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
  5. ncbi Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma
    J Marc Pipas
    Gastrointestinal Oncology Program, Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Ann Surg Oncol 12:995-1004. 2005

Collaborators

Detail Information

Publications5

  1. ncbi New targets and challenges in the molecular therapeutics of cancer
    Alan Eastman
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH 03756, USA
    Br J Clin Pharmacol 62:5-14. 2006
    ..These and many other challenges exist in the preclinical and clinical development of these drugs...
  2. ncbi Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center and University of Texas Health Science Center, San Antonio, Texas, USA
    Clin Cancer Res 13:3293-301. 2007
    ..v. infusion without premedication every 3 weeks, determine the maximum tolerated dose and the phase II recommended dose of AI-850, study the pharmacokinetics of paclitaxel in this new formulation, and seek evidence of anticancer activity...
  3. ncbi Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850)
    Raymond P Perez
    Section of Hematology Oncology, Department of Medicine, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 12:7079-85. 2006
    ..A phase I trial tested the hypothesis that UCN-01 abrogates cisplatin-induced cell cycle arrest (in tumors) at tolerable doses...
  4. ncbi Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers
    Ramesh K Ramanathan
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Cancer Chemother Pharmacol 57:465-74. 2006
    ..The pharmacokinetics of MGd were also evaluated...
  5. ncbi Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma
    J Marc Pipas
    Gastrointestinal Oncology Program, Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA
    Ann Surg Oncol 12:995-1004. 2005
    ..We conducted a phase II trial of dose-intense docetaxel and gemcitabine followed by twice-weekly gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma...